Cel-Sci/$CVM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cel-Sci
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
- Ticker
- $CVM
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 44
- Headquarters
- Vienna, United States
- Website
- cel-sci.com
Cel-Sci Metrics
BasicAdvanced
$23M
-
-$2.57
0.56
-
Price and volume
Market cap
$23M
Beta
0.56
52-week high
$7.80
52-week low
$0.89
Average daily volume
219K
Financial strength
Current ratio
1.477
Quick ratio
1.287
Long term debt to equity
0.474
Total debt to equity
0.721
Interest coverage (TTM)
-50.19%
Profitability
EBITDA (TTM)
-20.257
Management effectiveness
Return on assets (TTM)
-66.82%
Return on equity (TTM)
-252.53%
Valuation
Price to book
2.1
Price to tangible book (TTM)
2.12
Price to free cash flow (TTM)
-0.691
Free cash flow yield (TTM)
-144.68%
Free cash flow per share (TTM)
-1.895
Growth
Earnings per share change (TTM)
-71.71%
3-year earnings per share growth (CAGR)
-52.03%
10-year earnings per share growth (CAGR)
-32.72%
Cel-Sci Financial Performance
Revenues and expenses
Cel-Sci Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cel-Sci News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.